Lumara Health, which as KV Pharmaceutical emerged from Chapter 11 bankruptcy in September 2013, is to be split in two and acquired in separate transactions. In a deal worth up to US$1.025 B, AMAG Pharmaceuticals will buy the company’s maternal health business, including its flagship product Makena® (hydroxyprogesterone caproate injection), the only product approved by the US FDA to reduce the risk of preterm birth in at-risk pregnant women. In addition, OTC drug manufacturer Perrigo will buy Lumara’s women’s healthcare assets for US$82 M.